Neurodegenerative Diseases  >>  Catena (idebenone)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Catena (idebenone) / Chiesi
IONIA, NCT00537680: Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia

Completed
3
70
US
Idebenone, Placebo
Santhera Pharmaceuticals
Friedreich's Ataxia
04/09
04/09
MICONOS, NCT00905268 / 2005-004083-22: A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients

Completed
3
232
Europe
idebenone, Placebo
Santhera Pharmaceuticals
Friedreich's Ataxia
01/10
01/10
MICONOS Extension, NCT00993967 / 2007-001646-40: Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients

Completed
3
200
Europe
idebenone
Santhera Pharmaceuticals
Freidreich's Ataxia
06/12
06/12
PROTI, NCT01303406 / 2010-023388-16: Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone

Completed
3
29
Europe
Idebenone, Catena (approved name in Canada), Placebo
Santhera Pharmaceuticals
Friedreich's Ataxia
07/12
07/12
NCT01495715: Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)

Withdrawn
3
0
US
Idebenone, Placebo
Santhera Pharmaceuticals
Leber's Hereditary Optic Neuropathy
 
 

Download Options